Acumen Pharmaceuticals (NASDAQ:ABOS) Announces Earnings Results, Beats Expectations By $0.09 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS) issued its earnings results on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.09, FiscalAI reports.

Here are the key takeaways from Acumen Pharmaceuticals’ conference call:

• ALTITUDE-AD readout late 2026 — Acumen expects full efficacy and safety results from its phase II sabirnetug study this year, which the company says will inform its late‑stage development strategy and the broader Aβ‑oligomer hypothesis in AD.
• Preclinical EBD progress and funding — non‑human primate data showed 14–40‑fold higher brain levels for EBD candidates versus native antibody, the profiles exceeded targets, and a recent $35.75 million private placement was raised to advance the program toward an IND targeted in mid‑2027.
• Supportive Phase Ib biomarker signals — in INTERCEPT‑AD sabirnetug produced early CSF improvements (notably phospho‑tau‑181 and neurogranin) after three doses, which management views as supportive for potential phase II efficacy.
• Limited near‑term cash runway and high 2025 losses — year‑end cash and marketable securities of $116.9 million are expected to fund operations only into early 2027, and the company reported a $121.3 million net loss in 2025, implying additional financing will likely be needed to fully execute longer‑term plans.

Acumen Pharmaceuticals Stock Performance

Shares of ABOS stock opened at $2.48 on Thursday. The stock has a market capitalization of $150.33 million, a PE ratio of -1.10 and a beta of 0.21. The business’s 50 day simple moving average is $2.68 and its 200 day simple moving average is $2.15. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.02 and a quick ratio of 6.02. Acumen Pharmaceuticals has a one year low of $0.86 and a one year high of $3.60.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. BTIG Research boosted their price target on Acumen Pharmaceuticals from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Wall Street Zen downgraded shares of Acumen Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Friday, January 9th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Insider Transactions at Acumen Pharmaceuticals

In other news, CEO Daniel Joseph Oconnell sold 37,755 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $1.99, for a total value of $75,132.45. Following the transaction, the chief executive officer owned 619,982 shares in the company, valued at approximately $1,233,764.18. The trade was a 5.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 149,818 shares of company stock worth $285,057. 9.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Acumen Pharmaceuticals

Several large investors have recently modified their holdings of ABOS. Dimensional Fund Advisors LP grew its position in shares of Acumen Pharmaceuticals by 12.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 49,062 shares of the company’s stock worth $104,000 after buying an additional 5,538 shares during the period. Geode Capital Management LLC lifted its position in shares of Acumen Pharmaceuticals by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 410,206 shares of the company’s stock valued at $866,000 after acquiring an additional 11,428 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Acumen Pharmaceuticals during the third quarter worth $27,000. Marshall Wace LLP bought a new position in Acumen Pharmaceuticals during the fourth quarter worth $44,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Acumen Pharmaceuticals in the fourth quarter worth $47,000. 71.01% of the stock is currently owned by institutional investors and hedge funds.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.